Current Cardiology Reports

, Volume 4, Issue 4, pp 301–312

Glycoprotein receptor inhibitors in the management of acute coronary syndromes

  • Henock Saint-Jacques
  • Robert A. Harrington
Article

Abstract

Coronary thrombosis and the risk of clinical adverse events remains high despite considerable advances in the management of acute coronary syndromes (ACS) with the combined use of aspirin, heparin, fibrinolytic therapy, and percutaneous coronary intervention (PCI). Platelet aggregation and thrombosis play a key role in the pathogenesis of unstable coronary syndromes. Over the past several years, multiple placebocontrolled trials involving more than 50,000 ACS patients have shown that blockade of the platelet receptor glycoprotein (GP) IIb/IIIa, the final pathway in platelet aggregation, reduces the incidence of ischemic complications among patients with ACS. Three agents (abciximab, eptifibatide, and tirofiban) are currently approved for use with aspirin and heparin in the management of ACS or during percutaneous coronary intervention. They have consistently been shown to reduce the incidence of death or myocardial infarction in the ACS population including the patients not routinely scheduled for early revascularization. They provide an augmented treatment effect among high-risk ACS patients, particularly those who have a baseline troponin-t-positive status. Recently published practice guidelines have recommended their use in high-risk patients with ACS and all those undergoing PCI.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Heart and Stroke Facts: 1996 Statistical Supplement. Dallas: American Heart Association; 1996.Google Scholar
  2. 2.
    Topol EJ, Califf R, Granger C, et al.: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996, 335:775–782.CrossRefGoogle Scholar
  3. 3.
    PARAGON Investigators: International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998, 97:2386–2395.Google Scholar
  4. 4.
    Boersma E, Harrington RA, Moliterno DJ, et al.: Platelet glycoprotein IIb-IIIa Inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002, 359:189–198. This is an exceptional systematic review of large randomized trials highlighting the role of GP IIb/IIIa inhibitors in reducing cardiac complications in patients with ACS who were not routinely scheduled to undergo early coronary revascularization. This review observed a differential treatment effect of GP IIb/IIIa inhibitors between men and women with ACS which agrees with an observation from the PURSUIT trial of sex difference marking presence of significant CAD.PubMedCrossRefGoogle Scholar
  5. 5.
    Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995, 332:1553–1559.PubMedCrossRefGoogle Scholar
  6. 6.
    PRISM-PLUS study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998, 338:1488–1497.CrossRefGoogle Scholar
  7. 7.
    PRISM Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998, 338:1498–1505.CrossRefGoogle Scholar
  8. 8.
    Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995, 332:1553–1559.PubMedCrossRefGoogle Scholar
  9. 9.
    Tcheng JE, Ellis SG, George BS, et al.: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994, 90:1757–1764.PubMedGoogle Scholar
  10. 10.
    Mascelli MA, Worley S, Veriabo NJ, et al.: Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation. 1997, 96:3860–3866.PubMedGoogle Scholar
  11. 11.
    Mascelli MA, Lance ET, Damaraju L, et al.: Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 1998, 97:1680–1688.PubMedGoogle Scholar
  12. 12.
    Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest. 1997, 99:1467–1471.PubMedCrossRefGoogle Scholar
  13. 13.
    Simon DI, Xu H, Ortlepp S, et al.: 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997, 17:528–535.PubMedGoogle Scholar
  14. 14.
    Harrington RA, Kleiman NS, Kottke-Marchant K, et al.: Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995, 76:1222–1227.PubMedCrossRefGoogle Scholar
  15. 15.
    Kereiakes DJ, Kleiman NS, Ambrose J, et al.: Randomized, double- blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996, 27:536–542.PubMedCrossRefGoogle Scholar
  16. 16.
    Kouns WC, Kirchhofer D, Hadvary P, et al.: Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood. 1992, 80:2539–2547.PubMedGoogle Scholar
  17. 17.
    Van Hout BA, Bowman L, Zelinger DJ, Simoons ML: Costs and effects in therapy for acute coronary syndromes. Eur Heart J 1998, 19(Suppl D):D59-D66.PubMedGoogle Scholar
  18. 18.
    Mark DB, Harrington RA, Lincoff AM, et al.: Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation. 2000, 101:366–371.PubMedGoogle Scholar
  19. 19.
    Topol EJ, Mark DB, Lincoff AM, et al.: Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting. Lancet 1999, 354:2019–2024.PubMedCrossRefGoogle Scholar
  20. 20.
    Topol EJ, Moliterno DJ, Herrmann HC, et al Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001, 344:1879–1887.CrossRefGoogle Scholar
  21. 21.
    Wu AH: A comparison of cardiac troponin T and cardiac troponin I in patients with acute coronary syndromes. Coron Artery Dis. 1999, 10:69–74.PubMedGoogle Scholar
  22. 22.
    The PRISM-PLUS Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998, 338:1488–1497.CrossRefGoogle Scholar
  23. 23.
    The PURSUIT Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998, 339:436–443.CrossRefGoogle Scholar
  24. 24.
    Harrington RA, Lincoff MA, Berdan LG, et al.: Maintenance of clinical benefit at six-months in patients treated with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event. Circulation 1998, 98:I-359.Google Scholar
  25. 25.
    The PARAGON Investigators: International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998, 97:2386–2395.Google Scholar
  26. 26.
    Moliterno DJ: Patient-specific dosing of IIb -IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON-B study. Am Heart J. 2000, 139:563–566.PubMedCrossRefGoogle Scholar
  27. 27.
    The PARAGON-B Investigators: Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation. 2002, 105:316–321.CrossRefGoogle Scholar
  28. 28.
    Mahafrey KW, Roe MT, Dyke CK, et al.: Misreporting of myocardial infarction endpoints: results of adjudication by a central clinical events committee in the PARAGON-B trial. Am Heart J 2002, 143:242–248.CrossRefGoogle Scholar
  29. 29.
    The GUSTO IV-ACS Investigators: Effect of glycoprotein IIb/IIIa receptor abciximab on outcome in patients with acute coronary sydromes without early coronary revascularization: the GUSTO IV-ACS randomised trial. Lancet. 2001, 357:1915–1924.CrossRefGoogle Scholar
  30. 30.
    Bhatt DL, Topol E: Current role of platelet glycoprotein IIb- IIIa inhibitors in acute coronary syndromes. JAMA. 2000, 284:1549–1558.PubMedCrossRefGoogle Scholar
  31. 31.
    Roe MT, Harrington RA, Prosper DM, et al.: Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. Circulation. 2000, 102:1101–1106.PubMedGoogle Scholar
  32. 32.
    Santopinto J, Tajer C, Bozovich GE, et al.: Prior aspirin users are at increased risk of cardiac events and should be treated with enoxaparin. Circulation. 1999, 100:I-620.Google Scholar
  33. 33.
    Lancater GI, Lancaster CJ, Barr E, et al.: Prior aspirin use in unstable coronary syndromes results in a lower incidence of non-Q wave MI but a higher rate of medical therapy failure with unfractionated heparin: the aspirin paradox. Int J Cardiol 2001, 80:201–217.CrossRefGoogle Scholar
  34. 34.
    Alexander JH, Harrington RA, Tuttle RH, et al.: Prior aspirin use predicts worse outcomes in patients with non-ST elevation acute coronary syndromes. Am J Cardiol. 1999, 83:1147–1151.PubMedCrossRefGoogle Scholar
  35. 35.
    Hamm CW, Heeschen C, Goldmann B, et al.: Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999, 340:1623–1629.PubMedCrossRefGoogle Scholar
  36. 36.
    Heeschen C, Hamm CW, Goldmann B, et al.: Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999, 354:1757–1762.PubMedCrossRefGoogle Scholar
  37. 37.
    Newby KL, Ohman EM, Christenson RH, et al., for the PARAGON- B Investigators: Benefit of GP IIb-IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. Circulation. 2001, 103:2891–2896. This the first prospective study showing elevated troponin level as a marker for enhanced treatment benefit with GP IIb/IIIa inhibitors among patients with non-ST-elevation ACS.PubMedGoogle Scholar
  38. 38.
    Antman EM, Cohen M, Bernink PJ, et al.: The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000, 284:835–842.PubMedCrossRefGoogle Scholar
  39. 39.
    Ohman EM, Armstrong PW, Christenson RH, et al.: Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996, 335:1333–1341.PubMedCrossRefGoogle Scholar
  40. 40.
    Heeschen C, Van den Brand MJ, Hamm CW, Simoons ML: Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation. 1999, 100:1509–1514.PubMedGoogle Scholar
  41. 41.
    Boersma E, Akkerhuis KM, Theroux P, et al.: Platelet glycoprotein IIb/IIIa receptor inhibition in non- ST-elevation acute coronary syndromes. Circulation. 1999, 100:2045–2048.PubMedGoogle Scholar
  42. 42.
    Barr E, Thornton AR, Sax FL, et al.: Benefit of tirofiban + heparin therapy in unstable angina/non-Q-wave myocardial infarction patients is observed regardless of interventional treatment strategy. Circulation. 1998, 98:I-504.Google Scholar
  43. 43.
    Hudson M, Greenbaum EB, Harrington RA, Ohman EM: Use of glycoprotein IIb-IIIa inhibition plus fibrinolysis in acute myocardial infarction. J Thromb Thrombolysis. 1999, 7:241–245.PubMedCrossRefGoogle Scholar
  44. 44.
    Kamat SG, Schafer AL: Antiplatelet effects of fibrinolytic agents: a potential contributor to the hemostatic defect after thrombolysis. Coron Artery Dis. 1995, 6:930–935.PubMedGoogle Scholar
  45. 45.
    Winters KJ, Santoro SA, Miletich JP, Eisenberg PR: Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation. 1991, 84:1552–1560.PubMedGoogle Scholar
  46. 46.
    Kleiman NS, Ohman EM, Califf RM, et al.: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial infarction (TAMI) 8 pilot study. J AM Coll Cardiol. 1993, 22:381–389.PubMedCrossRefGoogle Scholar
  47. 47.
    Ohman EM, Kleiman NS, Gacioch G, et al.: Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb-IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation. 1997, 95:846–854.PubMedGoogle Scholar
  48. 48.
    The PARADIGM Investigators: Combining thrombolysis with the platelet glycoprotein IIb-IIIa inhibitor Lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose investigation and Reperfusion Gain in Myocardial infarction (PARADIGM) trial. J Am Coll Cardiol. 1998, 32:2003–2010.CrossRefGoogle Scholar
  49. 49.
    Antman EM, Gliugliano RP, McCabe CH, et al.: Abciximab (Reopro) potentiates thrombolysis in ST-elevation myocardial infarction: results of TIMI 14 trial. J Am Coll Cardiol. 1998, 31(Suppl A):191A.CrossRefGoogle Scholar
  50. 50.
    Lincoff AM, Califf RM, Anderson KM, et al.: Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol. 1997, 30:149–156.PubMedCrossRefGoogle Scholar
  51. 51.
    The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997, 336:1689–1696.CrossRefGoogle Scholar
  52. 52.
    Muhlestein JB, Karagounis LA, Treehan S, Anderson JL: "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol. 1997, 30:1729–1734.PubMedCrossRefGoogle Scholar
  53. 53.
    Haase KK, Mahrholdt H, Schroder S, et al.: Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty. Am Heart J 1999, 137:234–240.PubMedCrossRefGoogle Scholar
  54. 54.
    Van den Brand M, Laarman GJ, Steg PG, et al.: Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Eur Heart J. 1999, 20:1572–1578.PubMedCrossRefGoogle Scholar
  55. 55.
    O’Shea JC, Tcheng JE: Eptifibatide in Percutaneous Coronary Intervention. The Esprit trial results. Curr Interv Cardiol Rep 2001, 3:62–68.PubMedGoogle Scholar
  56. 56.
    O’Shea JC, et al., for the ESPRIT Investigators: Platelet glycoprotein IIb-Iia integrin blockade with eptifibatide in coronary stent intervention: a randomized controlled trial. JAMA 2001, 285:2468–2473.PubMedCrossRefGoogle Scholar
  57. 57.
    Raymond RE, Lincoff AM, Booth JE, et al.: Coronary bypass surgery within 12 hours of administration of abciximab remains safe despite an increased risk of perioperative bleeding. Eur Heart J. 1998, 19:238.Google Scholar
  58. 58.
    Lincoff AM, et al., for the EPILOG and EPISTENT investigators: Abciximab and bleeding during coronary bypass surgery: Results from the EPILOG and EPISTENT Trials. Ann Thorac Surg. 2000, 70:516–526.PubMedCrossRefGoogle Scholar
  59. 59.
    Marso SP, Bhatt DL, Roe MT, et al.: Enhanced efficacy of eptifibatide administration to patients with an acute coronary syndrome requiring in-hospital coronary artery bypass grafting. Circulation. 2002, 102:2952–2958.Google Scholar
  60. 60.
    The TIMI IIIB investigators: Effects of tissue plasminogen activator and comparaison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction. Circulation. 1994, 89:1545–1556.Google Scholar
  61. 61.
    Boden WE, O’Rourke RA, Crawford MH, et al., for the Veterans Affairs Non-Q-wave infarction strategies in hospital (VANQWISH) Trial Investigators: Outcomes in patients with acute non-Q wave MI randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998, 338:1785–1792.PubMedCrossRefGoogle Scholar
  62. 62.
    FRISC II Investigators: Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomized multicenter study. Lancet. 1999, 354:708–715.CrossRefGoogle Scholar
  63. 63.
    Canon CP, Weintraub WS, Demopoulos LA, et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb-IIIa inhibitor tirofiban. N Eng J Med. 2001, 344:1879–1894.CrossRefGoogle Scholar
  64. 64.
    Bodeb WE: Interpreting new treatment guidelines for non-ST segment elevation acute coronary syndromes. Am J Cardiol 2001, 88:19K-24K.Google Scholar
  65. 65.
    The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997, 349:1429–1435.CrossRefGoogle Scholar
  66. 66.
    Ferguson JJ III: Meeting highlights: XIXth Congress of the European Society of Cardiology. Circulation. 1997, 96:3818–3821.Google Scholar
  67. 67.
    Topol EJ: Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation. 1998, 97:211–218.PubMedGoogle Scholar
  68. 68.
    Phillips DR, Teng W, Arfsten A, et al.: Effect of Ca2+ on GP IIb- IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reduction in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997, 96:1488–1494.PubMedGoogle Scholar
  69. 69.
    Phillips DR, Scarborough RM: Clinical pharmacology of eptifibatide. Am J Cardiol. 1997, 80:11B-20B.PubMedCrossRefGoogle Scholar
  70. 70.
    Watanabe K, Ono F: Current status and problems of platelet function tests. Jpn J Clin Pathol. 1992, 40:507–514.Google Scholar
  71. 71.
    Becker RC, Cannon CP, Tracy RP, et al.: Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction. Am Heart J. 1996, 131:421–423.PubMedCrossRefGoogle Scholar
  72. 72.
    Harrington RA, Ohman EM, Sigmon KN, et al.: Intensity of inhibition of the platelet glycoprotein IIb/IIIa receptor differs among disease states [abstract]. Circulation. 1995, 92(Suppl I):I–488-I–489.Google Scholar
  73. 73.
    Coller BS: Platelets and thrombolytic therapy. N Engl J Med 1990, 322:33–42.PubMedCrossRefGoogle Scholar
  74. 74.
    The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997, 336:1689–1696.CrossRefGoogle Scholar
  75. 75.
    Steinhubl SR: Assessing the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary intervention. J Thromb Thrombolysis. 2000, 9:199–205.PubMedCrossRefGoogle Scholar
  76. 76.
    Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994, 308:81–106.Google Scholar
  77. 77.
    Eikelboom JJ, Anand SS, Malmberg K, et al.: Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000, 355:1936–1942.PubMedCrossRefGoogle Scholar
  78. 78.
    The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494–502.CrossRefGoogle Scholar
  79. 79.
    Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease Investigators: Long-term low-molecularmass heparin in unstable coronary-artery disease. Lancet 1999, 354:701–707.CrossRefGoogle Scholar
  80. 80.
    Cohen M, Theroux P, Weber S, et al.: Evaluation of combination therapy with tirofiban and enoxaparin in patients with unstable angina and non-Q-wave myocardial infarction. Eur Heart J. 1999, 20:376.Google Scholar
  81. 81.
    Tramuta DA, Kereiakes DJ, Dippel EJ, et al.: Combination enoxaparin-abciximab therapy during coronary intervention. J Invasive Cardiol. 2000, 12(Suppl C):3C-6C.PubMedGoogle Scholar
  82. 82.
    Kereiakes DJ, Fry E, Matthai W, et al.: Combination enoxaparin and abciximab therapy during percutaneous coronary intervention. J Invasive Cardiol. 2000, 12(Suppl A):1A-5A.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Henock Saint-Jacques
    • 1
  • Robert A. Harrington
    • 1
  1. 1.Duke Clinical Research InstituteDurhamUSA

Personalised recommendations